Decision Timeline: Considerations in Selecting an Outsourced Solution

August 30, 2017

Author: Gavin Murdoch, Senior Director, Strategic Partnerships, Global Business Management, Patheon

The traditional business model for in-house pharmaceutical manufacturing is nearly a thing of the past. More companies are turning to outsourcing to achieve flexibility and efficiency in a highly competitive market.

Learn how companies that ultimately decide to outsource often underestimate the time required once the decision has been made.

Case Study – Collegium Pharmaceutical’s Approach to Abuse Deterrence Breaks New Ground

The opioid abuse epidemic is a serious public health crisis that demands action on the part of many stakeholders. While abuse-deterrent opioids will not solve the opioid abuse epidemic alone, they play a critical role in the fight against it. While Collegium had come up with an innovative new approach to abuse deterrent formulations, it did not have the capacity or resources to manufacture its drug on a commercial scale.

Softgel Innovation and Unique OTC Solution

Learn about Patheon’s full dose form capabilities and technologies, including various tablets, caplets, chewables, powders, softgels, and more. Leverage Patheon’s broad range of expertise, from pre-formulation through commercialization, to help your project achieve success.

Technology Transfers: Reaping Rewards, Reducing Risks

In 2016, Patheon successfully completed 111 technology transfers to help our clients safeguard supply, improve distribution and reduce program costs and risks. This has allowed firms to take advantage of specialist expertise, solid processes and standardized operating procedures and equipment.

Case Study – Fighting The Opioid Epidemic: How Grünenthal’s Abuse-Deterrent Technology Contributes

As part of the FDA’s efforts to address opioid addiction, the agency put an opioid action plan into effect in 2011 to “reduce opioid abuse, dependence, and overdose in the United States.” Part of this plan included a call to pharmaceutical manufacturers to develop and expand access to abuse-deterrent formulations (ADFs) in order to discourage abuse among patients and promote innovation in the industry.

Solving the OOS Problem with Continuous Manufacturing

The goal of Pharmaceutical Process design has long been to implement a fixed process that can produce on-spec materials, which can be confirmed by quality testing.

Impact of Incorrect Forecasts on New Product Launches

Pharmaceutical companies around the world are under tremendous pressure – from regulators, legislators, payers, and patients – to reduce the cost of drugs. In response to the outcry for cost-cutting, pharmaceutical company leaders are examining every aspect of their business to determine where they can derive savings, particularly when planning for the launch of a new product.

Case Study – How Pacira Pharma Is Working To Help Curb The Opioid Epidemic

Poorly managed postoperative pain can have a significant impact on a patient’s recovery. Consequently, more patients relying in opioids furthers compounds the opioid epidemic. This case study discusses how Patheon and Pacira Pharma partnered to help curb this epidemic.

Solid and Sterile Dose Form Brochure

Oral Solids. Access a remarkable range of conventional and specialized oral solid dosage form capabilities and scale. Further expand your options with innovative combinations of these forms and a variety of controlled-release technologies.

Drug Substance

Drug Product

Small Molecule API Development

Oral Solid Dose

Softgels

Large Molecule Biologics Development

Steriles

Innovative Solutions